Skip to main content
. 2021 Oct 14;7:94. doi: 10.1038/s41531-021-00239-x

Fig. 3. Dopamine-catecholaminergic pathway.

Fig. 3

The metabolites highlighted in bold have been targeted and detected in this study. Both Tyr and l-DOPA are significantly increased in iPD patients (arrows and text in green). TH tyrosine hydroxylases, DDC dopa decarboxylase, MOA monoamine oxidase, DOPAL 3,4-dihydroxyphenylacetaldehyde; toxic intermediate, ALDH aldehyde dehydrogenase, DOPAC 3,4-dihydroxyphenylacetic acid and COMT catechol-O-methyltransferase.